Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 03, 2022

Pyrotinib Plus Capecitabine for Patients With HER2-Positive Breast Cancer and Brain Metastases

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Lancet Oncol 2022 Jan 24;[EPub Ahead of Print], M Yan, Q Ouyang, T Sun, L Niu, J Yang, L Li, Y Song, C Hao, Z Chen, A Orlandi, N Ishii, K Takabe, G Franceschini, F Ricci, C Verschraegen, Z Liu, M Zhang, H Lv, L Liu, X Yang, H Xiao, Z Gao, X Li, F Dong, X Chen, J Qiao, G Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading